Divi's Laboratories continues to be one of the highest-quality pharmaceutical businesses in India

Backed by a debt-free balance sheet, industry-leading margins, and a strong global reputation in APIs and custom synthesis (CDMO). The company has consistently demonstrated operational excellence, making it a long-term compounder rather than a cyclical pharma bet. Several factors support a bullish outlook: • Strong CDMO Opportunity: Global pharmaceutical companies are increasingly outsourcing manufacturing to reliable partners. Divi's is among the preferred suppliers because of its quality standards, regulatory compliance, and execution capabilities. • China+1 Tailwind: Customers continue diversifying their supply chains beyond China. India is a key beneficiary, and Divi's is well-positioned to capture this structural shift. • Capacity Expansion: The company has invested significantly in manufacturing infrastructure. As these capacities get utilized over the coming years, operating leverage can support earnings growth. • Healthy Financials: High return ratios, robust free cash flow generation, negligible debt, and a large cash balance provide financial flexibility while reducing downside risk. • Strong Export Franchise: A significant portion of revenue comes from global markets, giving the company exposure to international pharmaceutical demand and diversified revenue streams. • Innovation & Process Chemistry: Divi's has built deep expertise in complex chemistry and efficient manufacturing processes, creating high entry barriers for competitors. • Long-Term Industry Growth: Increasing healthcare spending, rising chronic diseases, and greater demand for generic medicines globally support sustained API demand over the next decade. Risks to Monitor USFDA or regulatory observations at manufacturing facilities. Pricing pressure in generic APIs. Delay in commercialization of new projects. Currency fluctuations affecting export earnings. Slower-than-expected CDMO order inflows.